Zhengfeng Wang
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Strategies for engineering oncolytic viruses to enhance cancer immunotherapy.
Journal: Frontiers in pharmacology
Published: June 17, 2024
Identifying drug candidates for pancreatic ductal adenocarcinoma based on integrative multiomics analysis.
Journal: Journal of gastrointestinal oncology
Published: December 27, 2023
miRNA-142-3p aggravates hydrogen peroxide-induced human umbilical vein endothelial cell premature senescence by targeting SIRT1.
Journal: Bioscience reports
Published: August 30, 2023
Analysis of Clinical Characteristic and Risk Factors for Short-Term Prognosis of Moyamoya Disease with Intraventricular Hemorrhage in Adults.
Journal: World neurosurgery
Published: October 11, 2022
M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy.
Journal: Frontiers in pharmacology
Published: September 23, 2022
Risk Factors for and Outcomes of Postoperative Entrapped Temporal Horn in Trigone Meningiomas.
Journal: Neurology India
Published: July 22, 2022
MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis.
Journal: Experimental & molecular medicine
Published: February 19, 2022
Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis.
Journal: Frontiers in cell and developmental biology
Published: January 28, 2021
Bit1 Silencing Enhances the Proliferation, Migration, and Invasion of Glioma Cells Through Activation of the IL-6/STAT3 Pathway.
Journal: OncoTargets and therapy
Published: November 27, 2019
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Journal: Life sciences
Published: July 26, 2019
Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Journal: Pharmaceutical research
Published: May 04, 2019
Last Updated: 09/26/2026